Conditions: Chronic Hepatitis C
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 95
Healthy volunteers: no

Brief summary:
The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of daclatasvir in subjects with chronic hepatitis C infection

Detailed description:

Arms:
arm 1: Daclatasvir - 1 mg

Placebo - 0 mg arm 2: Daclatasvir - 10 mg

Placebo - 0 mg arm 3: Daclatasvir - 100 mg

Placebo - 0 mg arm 4: Daclatasvir - 0.5 - 200 mg (to be determined)

Placebo - 0 mg

Interventions: intervention 1: Daclatasvir intervention 2: Placebo
Intervention descriptions: intervention 1: Oral Solution, Oral, Single Dose intervention 2: Oral Solution, Oral, Single Dose

Protocol document: